0000000000335055

AUTHOR

A. Di Cataldo

TUMORI a CELLULE GERMINALIin ETA' PEDIATRICA: FATTORI PROGNOSTICI del PROTOCOLLO AIEOP TCG 91.

CIRCA IL 20% DEI PAZIENTI CON TUMORI A CELLULE GERMINALI (tcg) SONO RESISTENTI AL TRATTAMENTO. GLI aUTORI HANNO EFFETTUATO UNO STUDIO POLICENTRICO AL FINE DI RILEVARE CORRELAZIONI TRA PARAMETRI CLINOCO/LABORATORISTICI E LA PROGNOSI

research product

FAILURE of TERATMENT in CHILDHOOD EXTRACRANIAL and EXTRATESTICULAR MALIGNANT GERM CELL TUMOURS (mgct)

Platinum based chemptherapy improves the cure rate of patients with MGCT to over 80 poer cent, but tumour recurrence is associated with an unfavourable prognosis. We sought to identify factors predicitive of poor outcome following relapse.

research product

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)

BACKGROUND: In neuroblastoma (NB), the presence of segmental chromosome alterations (SCAs) is associated with a higher risk of relapse. METHODS: In order to analyse the role of SCAs in infants with localised unresectable/disseminated NB without MYCN amplification, we have performed an array CGH analysis of tumours from infants enrolled in the prospective European INES trials. RESULTS: Tumour samples from 218 out of 300 enroled patients could be analysed. Segmental chromosome alterations were observed in 11%, 20% and 59% of infants enroled in trials INES99.1 (localised unresectable NB), INES99.2 (stage 4s) and INES99.3 (stage 4) (P<0.0001). Progression-free survival was poorer in patients wh…

research product

EXTRAGONADAL GERM CELL TUMORS: Results of AIEOP TCG 91/98 Protocols

The aim of the Study: To analyze the outcome of patirnts with extragonadal (eg) GCT teated with TCG 91/98 Protocols. 45 pts were enrolled: 34 were females, 11 males; median age 17 months (range: 1-137 months)

research product

TERATOMA IMMATURO EXTRACRANICO: Risultati dello Studio Cooperativo AIEOP "TCG-91".

I Teratomi Immatuti sono tumori costituiti da tessuto non maligno ma con potenzialità evolutiva maligna. Gli Autori presentano i dati dello Studio Cooperativo "TCG-91".

research product